Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 23;41(28):4183-4189.
doi: 10.1016/j.vaccine.2023.05.029. Epub 2023 May 16.

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

Zhao-Hua Zhou  1 , Margaret M Cortese  2 , Jia-Long Fang  3 , Robert Wood  4 , Donna S Hummell  5 , Kimberly A Risma  6 , Allison E Norton  5 , Mark KuKuruga  7 , Susan Kirshner  1 , Ronald L Rabin  7 , Cyrus Agarabi  1 , Mary A Staat  8 , Natasha Halasa  9 , Russell E Ware  10 , Anna Stahl  9 , Maureen McMahon  8 , Peter Browning  11 , Panagiotis Maniatis  11 , Shanna Bolcen  11 , Kathryn M Edwards  9 , John R Su  2 , Sai Dharmarajan  1 , Richard Forshee  7 , Karen R Broder  2 , Steven Anderson  7 , Steven Kozlowski  12
Affiliations

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

Zhao-Hua Zhou et al. Vaccine. .

Abstract

Background: The mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely debated; understanding this serious adverse event is important for future vaccines of similar design. A mechanism proposed is type I hypersensitivity (i.e., IgE-mediated mast cell degranulation) to polyethylene glycol (PEG). Using an assay that, uniquely, had been previously assessed in patients with anaphylaxis to PEG, our objective was to compare anti-PEG IgE in serum from mRNA COVID-19 vaccine anaphylaxis case-patients and persons vaccinated without allergic reactions. Secondarily, we compared anti-PEG IgG and IgM to assess alternative mechanisms.

Methods: Selected anaphylaxis case-patients reported to U.S. Vaccine Adverse Event Reporting System December 14, 2020-March 25, 2021 were invited to provide a serum sample. mRNA COVID-19 vaccine study participants with residual serum and no allergic reaction post-vaccination ("controls") were frequency matched to cases 3:1 on vaccine and dose number, sex and 10-year age category. Anti-PEG IgE was measured using a dual cytometric bead assay (DCBA). Anti-PEG IgG and IgM were measured using two different assays: DCBA and a PEGylated-polystyrene bead assay. Laboratorians were blinded to case/control status.

Results: All 20 case-patients were women; 17 had anaphylaxis after dose 1, 3 after dose 2. Thirteen (65 %) were hospitalized and 7 (35 %) were intubated. Time from vaccination to serum collection was longer for case-patients vs controls (post-dose 1: median 105 vs 21 days). Among Moderna recipients, anti-PEG IgE was detected in 1 of 10 (10 %) case-patients vs 8 of 30 (27 %) controls (p = 0.40); among Pfizer-BioNTech recipients, it was detected in 0 of 10 case-patients (0 %) vs 1 of 30 (3 %) controls (p >n 0.99). Anti-PEG IgE quantitative signals followed this same pattern. Neither anti-PEG IgG nor IgM was associated with case status with both assay formats.

Conclusion: Our results support that anti-PEG IgE is not a predominant mechanism for anaphylaxis post-mRNA COVID-19 vaccination.

Keywords: Anaphylaxis; Antibodies; COVID 19; IgE; Polyethylene glycol; mRNA vaccines.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mary A Staat reports a relationship with Pfizer that includes: funding grants. Mary A Staat reports a relationship with Merck & Co Inc that includes: funding grants. Mary A Staat reports a relationship with UpToDate that includes: consulting or advisory. Donna S. Hummell reports a relationship with Merck & Co Inc that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Bionet that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with IBM that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Member Data that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roache, Novavax, Brighton Collaboration that includes: consulting or advisory. UpToDate fees for Mary A. Stadt were classified as royalties that are unrelated to this work. Consultative work by Kathryn M. Edwards for X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roche, Novavax, Brighton Collaboration was serving on Safety and Monitoring Boards. Consultative work by Donna S. Hummel for Merck was for eDMC monitoring for clinical trial.

Similar articles

See all similar articles

Cited by

References

    1. Kelso J.M. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines. Vaccine. 2021;39(6):865–867. - PMC - PubMed
    1. Greenhawt M., Abrams E.M., Shaker M., Chu D.K., Khan D., Akin C., et al. The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J Allergy Clin Immunol Pract. 2021;9(10):3546–3567. - PMC - PubMed
    1. Shimabukuro T.T., Cole M., Su J.R. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325:1101–1102. - PMC - PubMed
    1. Klein N.P., Lewis N., Goddard K., Fireman B., Zerbo O., Hanson K.E., et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390. - PMC - PubMed
    1. McNeil M.M., Weintraub E.S., Duffy J., Sukumaran L., Jacobsen S.J., Klein N.P., et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–878. - PMC - PubMed

Publication types